CMC Biologics and IDT Biologika expand ADC manufacturing collaboration

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Choreograph)
(Image: iStock/Choreograph)

Related tags: Monoclonal antibodies

CMC Biologics and IDT Biologika have added Cerbios-Pharma SA and Oncotec Pharma Produktion GmbH to the companies’ PROVEO Partnership – a strategic collaboration for manufacturing antibody drug conjugates (ADCs).

According to the companies, with its new members the partnership will now be able to support the development and manufacture of complex ADCs from drug substance to final drug product.

PROVEO also offers project management, supply chain system, and quality systems.

As part of the partnership, CMC Biologics provides monoclonal antibody production and IDT Biologika performs analytical services, supply chain and secondary packaging through to final drug product.

Moving forward, Cerbios will carry out process development, manufacture of the cytotoxic drug-linker payload, in addition to providing conjugation services of the ADC drug substance. Oncotec will provide aseptic fill and lyophilization of the ADC drug product.

The services will be available through the PROVEO Partnership in early 2017.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Related suppliers

Follow us


View more